

AdvaNeedle

Advanced Ultrasonic Fine-Needle for Biopsy

Biopsy is the golden standard of **sampling tissue for diagnostic purposes**. Tens of millions biopsies are annually performed for cancer diagnosis and therapy plan. Biopsy device market size is 1,5 billion USD (2017) and growing steadily 7%/a.

Two main biopsy methods exist today and both have their shortcomings. Remarkable amount of biopsies fail because of not obtaining sufficient amount of tissue or there are safety concerns. This leads to delays in diagnosis and treatment, frustration among the patients and additional costs to the health care system.

AdvaNeedle provides new technology enabling biopsy with low trauma risk and good adequacy. In AdvaNeedle approach, we employ the existing working processes at hospitals and clinics, but introduce a new ultrasound enabled product concept for correcting the existing shortcomings.

SPARK VALUE: We expect SPARK to help us in finding the best approach for AdvaNeedle commercialization and for future funding. SPARK provides us valuable feedback from industrial partners, from fellow scientists and it's a great learning opportunity to hear about other similar projects.

Jouni Rantanen, MSc

AdvaNeedle project manager and responsible for commercialization. Jouni has a wide experience of product and business development in many industrial applications in top-notch Finnish technology companies.



Heikki Nieminen, Ph.D., Asst. Prof.

Responsible leader, adviser in medical ultrasonics and medtech start-ups. Heikki is Assistant Professor at the Aalto University in Biomedical Engineering and a co-founder in startup companies Photono Oy, Klinik Healthcare Solutions Oy and SWAN Cytologics Inc in Canada.